We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Tyco and Bard Terminate Merger

By HospiMedica staff writers
Posted on 11 Feb 2002
Print article
As investor concerns continue to grow over its financial condition, Tyco International Ltd. (Pembroke, Bermuda) has announced that the agreement to acquire C.R. Bard Inc. (Murray Hill, NJ, USA) for US$3.2 billion has been mutually terminated by both parties. Each party will bear its own costs. Bard is a supplier of medical devices and surgical specialty products. Tyco also announced that its earnings would not meet previous forecasts.

Several weeks earlier, Tyco had announced its intention to split into four separate companies, in part to satisfy investors concerned about its cash position, accounting practices, and falling stock prices. So far this year, Tyco's stock has fallen by more than 50%. The company is now trying hard to sell or spin off its finance unit, the CIT Group, to restore confidence in that unit. Although no accounting irregularities have been brought to light, some investors fear that Tyco is manipulating the earnings of companies it acquires so as to inflate Tyco's earnings artificially. Tyco denies any improper accounting.




Related Links:
Bard
Tyco
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Dry Thawing & Warming System
SAHARA-TSC 230 V
New
Ultrasound Table
Women’s Ultrasound EA Table

Print article

Channels

Surgical Techniques

view channel
Image: Graphical abstract; Surgical field during endomyocardial biopsy and fluoroscopic images (Photo courtesy of Heart Rhythm, DOI: 10.1016/j.hrthm.2024.10.069)

Novel Method Combining Heart Biopsy and Device Implantation Reduces Complications Risk

Endomyocardial biopsy (EMB) is a crucial diagnostic tool for identifying various cardiac conditions; however, it carries a risk of complications due to its invasive nature. New research has introduced... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.